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I. INTRODUCTION
The Food and Drug Administration (FDA) recognizes that, in the-
ory, through biotechnology "essentially any trait whose gene has been
identified can be introduced into virtually any plant . . . ."1 These
genes may potentially be isolated from microbial, animal or plant
sources. 2 The major uses of biotechnology to date in foods have in-
volved agronomic uses that enhance yield or protect crops from pests
or weeds. Some of these have involved gene transfers from the same
source, such as the use of a recombinant version of a cow hormone to
1. Statement of Policy: Foods Derived from New Plant Varieties; Notice, 57 Fed.
Reg. 22,984, 22986 (May 29, 1992) [hereinafter Statement of Policy].
2. See id.
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increase milk production. Widespread crop protection uses involve
the transfer of a bacterial pesticide gene to corn and a gene to enable
soybeans to survive spraying with an herbicide. 3
More novel uses of biotechnology are pending in addition to those
that are theoretically possible. Some involve transfers from different
plants to affect the taste and nutritional characteristics of the food
itself. Golden Rice, for example, produces Vitamin A derived from a
gene from a daffodil gene.4 Sweet potatoes may be modified to contain
amino acids. 5 In the past, field tests were even conducted on the
transfer of fish genes to a tomato to provide protection from frost dam-
age.6 Biotechnology may also be used in animals in new ways, includ-
ing to enhance the growth of salmon in fish farms.7 FDA has stated
that as a result of increased knowledge of the genome, biotechnology is
"likely" to be used "to an increasingly greater extent" by plant breed-
ers, and in some cases the products may present "more complex safety
and regulatory issues."8
3. See JORGE FERNANDEZ-CORNEJO & WILLIAM D. McBRIDE, ECONOMIC RESEARCH
SERVICE/USDA, ADoPrION OF BIOENGINEERED CROPS 4 (2002), available at http:fl
www.ers.usda.gov/publications/aer8lO (reporting that herbicide-tolerant soy and
corn use reached 68% and 8-9% respectively, of crop acreage in 2001. Insect-
resistant corn use reached 26% in 1999 and fell to 19% in 2000-01); infra Section
IV.C.
4. See Raymond Formanek, Jr., Proposed Rules Issued for Bioengineered Foods,
FDA CONSUMER, Mar-Apr. 2001, available at http://www.fda.gov/FDA/features/
2001/201_food.html (citing development of rice by inserting genes from soil bacte-
rium and two gene from a daffodil).
5. See generally Karen A. Goldman, Labeling of Genetically Modified Goods: Legal
and Scientific Issues, 12 GEO. INT'L ENVTL. L. REV. 717, 718-19 (2000) (describing
examples of the "'second generation'" genetically engineered foods).
6. See Statement of Policy, 57 Fed. Reg. at 22,986. Even though the plant has not
been developed, the labeling of the food is relevant here to explore the issues on a
theoretical level. For identification of field tests by public institutions on gene
transfers from animals to plants for drug or food-related purposes, see Richard
Caplan & Ellen Hickey, Weird Science, The Brave New World of Genetic Engi-
neering (U.S. Public Interest Research Group 2000). A number are related to
pest-protection and agronomic uses, such as tests on a transfer of a chicken gene
to apples to resist fire blight, and a cow gene to sugarcane to develop a plant
resistant to a disease-causing bacteria.
7. NATIONAL RESEARCH COUNCIL, ANIMAL BIOTECHNOLOGY: SCIENCE BASED CON-
CERNS 8 (National Academies Press 2002) (describing gene transfers presumably
from the same animal to lower cholesterol in eggs, or to increase yield by cloning
productive animals) [hereinafter NAS ANIMAL BIOTECHNOLOGY]. See also Associ-
ated Press, New Type Pigs in the Future: Genetic Engineering Could Develop
Porkers With Special Milk Traits, ROCKY MOUNTAIN NEWS, Apr, 14, 1996, at 32A,
cited in Michael A. Whittaker, Reevaluating the Food and Drug Administration's
Stand on Labeling Genetically-Engineered Foods, 35 SAN DIEGO L. REV. 1215,
1219 n.21 (1998).
8. Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. 4706, 4709 (pro-
posed Jan. 18, 2001) (to be codified at 21 C.F.R. pts. 192 and 592) [hereinafter
Premarket Notice]. The development of rice modified to express pro-vitamin A
was cited as an example of "more complicated compositional changes being made
1090
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FDA has not required any special labeling on foods about the mere
process of using biotechnology. Under its policy, labeling is needed,
apart from safety risks, only if the resulting food differs in a "mean-
ingful or uniform way" or "differs" in a way that the traditional name
no longer applies.9 The agency looks to is whether there are organo-
leptic differences in determining if there is a "material fact" that needs
to be disclosed in the name.1 0 The agency's position has been upheld
in court challenges in cases.1 1 Moreover, the effort by the state of Ver-
mont to mandate disclosures about the use of cow growth hormone
developed through biotechnology, based on consumer interest, was
found to lack a substantial government interest and to be an unconsti-
tutional form of compelled speech.12 The agency, though, permits vol-
untary labeling that bioengineering has not been used when it does
not misleadingly suggest a difference in safety.13
This Article examines whether the transfer of a gene from a differ-
ent species should affect the need for labeling of the food. The com-
plexities in developing a labeling framework are also explored. The
best case for additional labeling is when a gene has been transferred
from a different plant or animal species to a food to affect its taste or
nutrition. Will it be sufficient that a new food identifies its new qual-
ity features, or should the name and labeling in some way indicate
that the food has a gene from a different plant? One format explored
here would be a specific reference to a plant as a source of a trait. If
rice contained a sucrose gene, for example, the labeling would reflect
that the food is "rice with a plant sweetener." Another format is to
include the term "enhanced" in the name, by referring to "rice en-
hanced a with plant sweetener." With time and consumer familiarity,
the enhanced term might become a shorthand way to indicate the ad-
dition of genes to a food of genes from another edible plant. When a
gene from an animal or fish source is transferred to a plant, though,
to food," ones involving multiple genes, that could be connected with "unintended
changes." Id. at 4710.
Recently companies have been dropping projects involving the use of biotech-
nology to develop new crops because of the cost of obtaining agency approval and
consumer resistance. See Narrow Path for new Biotech Crops, New York Times,
C2 (May 20, 2004).
9. See Statement of Policy, 57 Fed. Reg. 22,984, 22,991 (May 29, 1992).
10. See Stauber v. Shalala, 895 F. Supp. 1178, 1193 (W.D. Wis. 1995).
11. See discussion infra Section III.B.
12. Int'l Dairy Foods Ass'n v. Amestoy, 92 F.3d 67 (2d Cir. 1996).
13. Draft Guidance for Industry: Voluntary Labeling Indicating Whether Foods Have
or Have Not Been Developed Using Bioengineering, 66 Fed. Reg. 4839, 4840 (Jan.
18, 2001). See infra note 155; Frankenstein Foods or Flavor Savors? Regulating
Agriculture Biotechnology in the United States and European Union, 7 VA. J. Soc.




the labeling should indicate specifically that an animal or fish gene
has been transferred.
The justification for the labeling explored here is the need to pre-
vent deception about important changes that affect consumer's under-
standing of the identity of the food. If consumers do not expect foods
to contain genes from a different species, a disclosure may be needed
under an early Supreme Court case, United States v. Ninety Five Bar-
rels of More or Less Alleged Apple Cider Vinegar.14 The Court found a
food to be mislabeled when a change was made in a constituent of the
food, a change that did not affect the food's taste but which made the
food differ from the popular and general understanding of "what [the
food] really is."15 The application of the deception theory to gene
transfers from different species involves a generous but fair reading of
this landmark precedent. The rationale is also different from the ar-
gument based simply on "consumer interest" about the mere use of
biotechnology found wanting in the past litigation.16
The theory that underlies this paper, tied as it is to the need for
labeling when a gene transfer makes a food "different," raises the com-
plication of determining what makes a food "different." Gene transfers
have occurred in plants for centuries through traditional plant breed-
ing, with its modern extensions, with no labeling changes ordinarily
needed. 17 Still, determining "difference" for purposes of labeling war-
rants consideration of whether a "wide cross" with a distant ancestor,
made feasible in practice through biotechnology, should be considered
the same as transfers using other extended techniques.
While the starting focus of this Article relates to gene transfers
from a different species to affect the taste and nutrition characteris-
tics of a food, the implications of the agronomic uses of biotechnology
need to be recognized. The pesticide uses of biotechnology can involve
gene transfers from different species, such as the transfer of a soil bac-
teria gene to corn. Plant pesticides could, in theory, be transferred to
a different plant as a means to control pests. If consumers are
deceived, absent disclosure, about transfers from a different species to
affect a food's taste or nutrition, should the principle apply to agro-
nomic uses? Special difficulties arise, though, in labeling agronomic
uses, since the crops are often shipped as commodities. Chemical pes-
ticides also have a special exemption from labeling as a chemical pre-
servative, an exemption that may affect FDA's willingness, and its
ability, to require labeling for the biotech pest protectors. Labeling
solely the biotechnology use could provide an incentive for use of
14. 265 U.S. 438 (1924).
15. Id. at 443.
16. See discussion infra Part III.
17. See discussion infra subsection IV.A.2; Statement of Policy, 57 Fed. Reg. 22,984,
22984 (May 29, 1992).
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chemical pesticides. While there is no fully satisfactory solution, a
suitable approach would be a label disclosure that a food contains a
"crop protector," whenever any type of pesticide or herbicide is used,
but without a specification of the type.' 8 The labeling would leave it
to consumers to obtain more information from the seller of the food.
Lastly, the Article considers a new use of biotechnology, one that
has a species connection, not because it involves a transfer from a dif-
ferent species but because the food developed through the process
could alter the natural species. Notably, FDA is considering a request
to allow a salmon growth hormone gene to be transferred to farm-
raised salmon to enhance growth, but the use raises environmental
concerns because of the potential impact on the wild salmon when
some of the larger transgenic salmon escape. A report by the National
Academy of Sciences found the environmental risk from transgenic
fish to be the most important "science-based" concern.19 Clearly, the
key regulatory questions relate to whether the use should be permit-
ted in light of this potential impact. This involves issues about the
agency's authority to regulate environmental risk and the measures
that might be taken to reduce the risk of escape. The other question
noted here is whether labeling disclosures are appropriate, assuming
the new use is permitted, to alert consumers of a consequence they
would not expect, that consumption of the bioengineered form of the
food could fundamentally change the natural unmodified form of the
species. That labeling might indicate that measures have been re-
quired to minimize the risk that the enhanced salmon will escape and
alter the wild salmon through interbreeding. That labeling is appro-
priate when the scope of the risk has important uncertainties that
need further monitoring. The labeling would permit consumers to be
involved in seeking alternatives to reduce the risk, including encour-
aging fish farm operators to be vigilant and to develop improved meth-
ods. Such an approach would give consumers an expanded role in risk
decisionmaking. When the use of a food by consumers has a potential
for a major change in the species itself, notice to consumers should be
considered in developing an appropriate response. While the paper
explores the legal rationale for requiring labeling under the existing
law for this and the other recommendations, legislative action should
also be considered.
Importantly, this Article does not deal with the debate about the
safety of biotechnology for the existing uses or novel ones, an impor-
18. However, a more specific designation would be needed if the agronomic use in-
volved the transfer of an animal or fish gene to a plant. See discussion infra sub-
section IV.A.2.
19. NAS ANIMAL BIOTECHNOLOGY, supra note 7.
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tant matter that has received analysis elsewhere.20 Environmental
issues are also not the primary focus, apart from the potential for an
impact on the unmodified species, a risk that may occur with the
transgenic salmon. 2 1 The aim is to explore the extent to which label-
ing can be justified to prevent deception, assuming that the biotech
food uses meet regulatory safety and environmental standards.2 2 The
paper also examines labeling policies under U.S. law, and does not
seek to compare the policies that European countries have developed
with respect to Genetically Modified (GM) Foods. The U.S. has,
though, instituted a proceeding in the World Trade Organization
against the European Union about its moratorium on genetically mod-
ified commodities. 23 The labeling policies in Europe have an impor-
20. For illuminating analysis of the safety issues, see Thomas 0. McGarity, Seeds of
Distrust: Federal Regulation of Genetically Modified Foods, 35 U. MICH. J. L. REF.
403, 489 (2002) (suggesting a more precautionary approach on safety and criticiz-
ing FDA's reliance on "substantial equivalence" as the test when new uses of bio-
technology require additional testing), and National Academy of Sciences,
Genetically Modified Pest-Protected Plants 6, 7-10 (National Academies Press
(2000)) [hereinafter NAS Pest Protected] (reporting that transgenic and conven-
tional methods "have the potential to produce organisms of high or low risk" and
the properties, not the process, should be the focus of risk assessments, and rec-
ommending ways to improve the health and related data). Compare Dan L.
Burk, The Milk Free Zone: Federal and Local Interests in Regulating Recombi-
nant bST, 22 COLUM. J. ENVTL. LAW 227 (1997) (defending scientific soundness of
use in milk production and examining "socioscientific" disputes). The transfers
from different species can make the safety assessments more complicated, as sug-
gested in Premarket Notice Concerning Bioengineered Foods. See 66 Fed. Reg.
4706 (proposed Jan. 18, 2001).
21. Environmental issues are discussed, in regard to genetically engineered salmon,
and are suggested as an additional ground for labeling. See discussion infra Sec-
tion IV.D.
22. Of course, it is true that if any labeling is provided about the use of biotechnology
to prevent deception, consumers may decide not to use the food for other reasons
including unsubstantiated ones. That complication can arise with respect to
other required labeling, such as ingredient labeling, but it is not a basis for dis-
pensing with labeling disclosures that are needed.
23. See David Leonhardt, Talks Collapse on U.S. Efforts to Open Europe to Biotech
Foods, Washington to Urge World Trade Group to Act, N.Y. TIMES, June 20, 2003,
at Al (noting that the U.S. negotiators viewed the E.U. effort as protectionist
since the technology is made by U.S. companies); John W. Boscariol & Orlando E.
Silva, Genetically Modified Organisms at Center of Major WTO Dispute THE LAW-
YERS WEEKLY 23 (Mar. 26, 2004); Frankenstein Foods, supra note 13. For back-
ground on the WTO procedures and on an earlier dispute between the U.S. and
the E.U. about the use of hormones in beef, see Joanne Scott, On Kith and Kine
(and Crustaceans): Trade and Environment in the EU and WTO, in THE EU, THE
WTO AND THE NAFTA, TOWARDS A COMMON LAW OF INTERNATIONAL TRADE 125
(2000).
The European Union has recently allowed the sale of corn developed through
biotechnology, accompanied by labeling, but the change is not expected to stop
the U.S. from pursing its proceeding with the WTO. EU Moves to Soften Its
Stance on Biotech Corn, WALL ST. J., INTERNATIONAL WORLD WATCH, May 20,
1994 (available at 2004 WL-WSJ 56929710).
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tant impact in the ability of U.S. producers to sell modified foods.24
The pendency of the dispute with Europe may lead to some greater
interest in understanding the U.S. labeling policy and how it applies
to novel types of food, the topic here.
To pursue the analysis, Part II will provide background on FDA
regulatory authority with respect to the safety of biotechnology when
used in developing new plant varieties or in animal drugs that pro-
mote growth and yield. The discussion will also outline the regulatory
responsibilities of the Environmental Protection Agency (EPA) with
respect to pesticide and herbicide uses. FDA's authority to require
consumer labeling on foods will be described, along with the basis for
the agency's policy of providing labeling about the use of biotechnology
in limited circumstances.
Part III examines the legal challenges that sought, unsuccessfully,
to require FDA to mandate additional labeling. The constitutional
challenge that invalidated Vermont's effort to require labeling about
biotechnology in milk production will also be considered. The discus-
sion will then consider the deception theory as the basis for reflecting
in the labeling of a food when there are gene transfers from different
species. That theory has a different premise from the consumer inter-
est found to be insufficient in the prior cases.
Part IV explores the type of labeling that might be adopted under
the deception theory for the novel uses of food biotechnology with a
species connection. The examination covers labeling of foods with
genes from different species to achieve quality or nutritional effects,
the special issues for pest-protected uses, and the appropriateness of
labeling transgenic salmon with respect to the potential of altering the
wild form of the species.
Part V concludes with some general observations on the need for
labeling of foods with genes from different species and the role of con-
sumers in making choices. Better labeling is needed to ensure that
consumers do not perceive food as being something different than they
believed it to be.
A note is appropriate on the terminology used here. FDA has re-
ferred to foods as being "bioengineered," and in Europe foods are re-
ferred to as genetically modified organisms (GMO). The National
Academy of Science referred to biotechnology, in the case of animal
drugs, a term that is also used for pharmaceuticals and in the press
for stock market reports. This paper generally refers to biotechnology
because it may be the term most familiar to the public, but the other
terms are also used in context.
24. See McGarity, supra note 20, at 502.
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II. REGULATORY FRAMEWORK FOR BIOTECHNOLOGY
IN FOODS
The authority to regulate the use of biotechnology uses in food is
divided. Discussed first is FDA's safety authority with respect to new
plant varieties and animal drugs for growth promotion. EPA's author-
ity with respect to pesticides will be noted before turning to an elabo-
ration of FDA's position on consumer labeling about biotechnology.
A. FDA Safety Authority with Respect to New Plant
Varieties
1. FDA Basis for Safety Regulation: The 1992 Policy Statement
FDA's authority over food safety extends to new plants, even those
developed by traditional plant breeding methods such as hybridiza-
tion. New substances added to foods need approval in advance from
the agency in the form of a regulation authorizing the "food additive,"
unless the substance is Generally Recognized As Safe (GRAS).25 FDA
ordinarily regards new plant varieties developed through traditional
plant breeding and its extensions as GRAS and, thus, as excluded
from being food additives that need prior approval
In a 1992 Policy Statement, FDA applied a similar approach to
new plant varieties developed through biotechnology. A gene added
through biotechnology was considered an "added" substance in the
food.26 The addition would not be considered to be a food additive for
which pre-market approval was needed, though, simply because the
transfer occurred through bioengineering. In determining whether
the substance was recognized as safe, the agency would look instead
at the transferred material and its expression products. 27 When the
substances produced in the food is "already present in the food at gen-
erally comparable levels," the agency believed there was "unlikely to
be a safety question sufficient to call into question the presumed
GRAS status of such naturally occurring substances."28 FDA identi-
fied transfers from known toxicants, activation of silent pathways,
and allergencity as having a potential for concern, but also considered
measures such as field testing practices as relevant in showing
25. Statement of Policy, 57 Fed. Reg. 22,984, 22,990 (May 29, 1992). As a GRAS
substance, the food would fall outside the definition of a food additive. See Fed-
eral Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 321(s), 348 (2003). If an unex-
pected safety problem occurred during use, FDA would take court or other action
under its basic authority over deleterious substance added to a food under 21
U.S.C. §342(a) (2000). See Statement of Policy, 57 Fed. Reg. at 22,989. A "public
hearing" is available with respect to objections to the issuance of regulations for
food additives. 21 U.S.C. § 348(f) (2000).





safety.29 There have been critics, though, of the "substantial equiva-
lence" approach used by FDA and other agencies to determine that a
bioengineered variety is as safe as the unmodified form.30 FDA also
stated that developers of new bioengineered varieties "should" consult
with FDA before use of the product, a practice that the industry is
believed to have followed.31
2. Emergent Uses and FDA's 2001 Proposal for Pre-Market
Notice
In 2001, FDA reported that most uses of biotechnology in foods in-
volved agronomic uses that increase yield,3 2 but that the use of bio-
technology is increasing as a means to affect a food's nutrition, flavor,
or preservation. 33 The agency noted that some field trials underway
involved changes intended "to modify the food itself,"3 4 and were ones
"more likely" to raise regulatory issues. 35 Moreover, an increasing
number of substances being tested for introduction into food are ones
"that cannot be introduced by traditional breeding," and create a
"greater likelihood" that the change is so significant that pre-market
approval for safety is needed.3 6 As a result, FDA proposed to mandate
consultation with FDA about the regulatory issues that can arise with
respect to new biotechnology uses and the need for pre-market
approval.3 7
That proposal illustrates a tension with respect to the regulatory
framework for GRAS determinations. If foods are GRAS, the producer
has been considered legally entitled to market the food, subject to the
risk that the agency will take enforcement action to have a court re-
solve the dispute about GRAS status.38 The proposal, though, would
require notification rather than simply letting producers to take the
29. Id. at 22,987.
30. See McGarity, supra note 20, at 432-38.
31. Id. at 22,991; Premarket Notice, 66 Fed. Reg. 4706, 4710 (proposed Jan. 18, 2001)
(to be codified at 21 C.F.R. pts. 192, 592).
32. Id. at 4711. FDA identified these as including "herbicide resistance, insect and
virus resistance, delayed ripening or softening, male sterility, or fertility restorer
and high phosphorus availability." Id. at 4712.
33. Statement of Policy, 57 Fed. Reg. 22,984, 22,985 (May 29, 1992).
34. Premarket Notice, 66 Fed. Reg. at 4711. These included modification of protein
quality, increased carotenoid solids, altered fiber, and increased fruit sweetness.
Id. at 4712.
35. Id. at 4711.
36. See id. at 4709. See Panel Sees No Unique Risk From Genetic Engineering, New
York Times, A13 ((July 26, 2004) (reporting the findings of a penal of the Na-
tional Academy of Sciences that bioengineered foods do not pose risks that cannot
arise with conventional breeding, but recommending post-market surveillance for
some changes that may have possible adverse health effects).
37. See id. at 4712-13.
38. See Statement of Policy, 57 Fed. Reg. at 22,989.
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litigation risk. The agency has not issued a final rule, but the volun-
tary cooperation of the industry is likely to lead to continued advance
consultation with the agency. The supporting field tests, and com-
ments on the testing, are also in practice made public on the FDA
home page, increasing the transparency of the process for the public
and the scientific community. 3 9 The most notable aspect of the propo-
sal in this setting, though, rests with the agency's projection that the
emerging uses may have differences from earlier ones. These develop-
ments may have implications for labeling as well as GRAS
determinations.
B. FDA Safety Regulation for Animal Biotechnology:
Growth and Yield Promotion 40
FDA also regulates the administration of biotech products used on
food-producing animals under its authority over animal drugs that are
used to affect the structure and function of the animal as well as those
that are used to prevent or treat disease. 4 1 Pre-market approval is
required for the license to use a new animal drug.42 The transparency
of the approval process is reduced, though, by the confidential status
of submissions. 4 3 One of the earliest forms of biotechnology approved
by FDA involved the use a recombinant form of a hormone naturally
produced in small amounts by cows to stimulate milk production. The
biotech version of a hormone found in cows, rBST, enabled injections
to induce further production for commercial use.4 4 FDA's approval of
rBST without requiring labeling set the stage for some of the court
challenges discussed below. The use of growth hormones for farm-
raised salmon also involves the use of an animal drug to affect the
salmon and necessitates FDA pre-market approval. The environmen-
tal issues raised by the effort to obtain approval will be discussed in
Section IV.D.
C. Pest and Crop Protection Uses of Biotechnology
A major category of biotechnology used in food involves a gene
transfer into a plant that provides protection for the food from insects
during growth. The Environmental Protection Agency (EPA) regu-
39. Frankenstein Foods, supra note 13, at 274-75.
40. For general background on animal raising, even apart from the use of biotech
products, see Michael Pollan, This Steer's Life, NEW YORK TIMES MAGAZINE, Mar.
31, 2002, at 44.
41. 21 U.S.C. § 355 (2003).
42. 21 U.S.C. § 360(b) (2000). Procedurally, the matter approval involves a formal
adjudication, since the applicant is entitled to a hearing by statute.
43. Future Fish, Issues on the Science and Regulation of Transgenic Fish [PEW INITIA-
TIVE ON FOOD AND BIOTECHNOLOGY] 52 (2002) [hereinafter Future Fish].
44. See Burk, supra note 20, at 230-31.
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lates the safety of all pest control products, both chemical and biotech,
under its authority over "chemical pesticides,"4 5 including those used
in foods. EPA now designates the biotechnology form of pest protec-
tion, not as a "Plant Pesticide," as it previously had done, but as
"Plant-Incorporated Protectants."4 6 FDA recognizes that EPA ad-
dresses under its authority "the food safety issues associated with the
pesticide."4 7 FDA enforces the EPA tolerances for pesticide in foods.
The Department of Agriculture has a separate, but debated, responsi-
bility to ensure that farmers meet restrictions set by EPA to guard
against the development of pesticide resistant species as the result of
new biotech pesticides.48
EPA has found several pest-protectants to be safe for use in plants,
through licensing approval or exemptions, including the use of Bacil-
lus thuringiensis (Bt) in soybeans. 49 Obtaining approvals for a new
chemical pesticide often costs substantially more than obtaining per-
mission for use of a transgenic pest-protected plant, making trans-
genic plants more attractive.50 EPA also regulates herbicides and
herbicide-resistant plants including those used for food.51 The cate-
gory includes Roundup Ready soybeans that have a gene that makes it
possible for farmers to spray the crop with the herbicide Roundup to
control weeds without harming the soybeans. 5 2
45. See Federal Environmental Pesticide Control Act, 7 U.S.C. §136-136y (1982);
United States Environmental Protection Agency, EPA's Regulation of Biotechnol-
ogy for Use in Pest Management (2003), available at http://www.epa.gov/pesti-
cides/biopesticides/regofbiotech/eparegofbiotech.htm. For analysis of legal
framework and implementation, see McGarity, supra note 20, at 464-73. For
analysis of the scientific issues, see NAS Pest-Protected, supra note 20, at 33.
46. Regulations Under the Federal Insecticide, Fungicide and Rodenticide Act for
Plant-Incorporated Protectants (Formerly Plant-Pesticides), 40 C.F.R. pt. 174
(2004).
47. Statement of Policy, 57 Fed. Reg. 22,984, 23,005 (May 29, 1992).
48. See Rebecca Bratspies, The Illusion of Care: Regulation, Uncertainty, and Geneti-
cally Modified Food Crops, 10 N.Y.U. ENVTL. L. J. 297, 307, 320 (2002) (criticizing
divided responsibilities and recommending a single regulatory authority), and
Gregory N. Mandel, Gaps, Inexperience, Inconsistencies, and Overlaps: Crisis in
the Regulation of Genetically Modified Plants and Animals, 45 WILLIAM & MARY
L. REV. 2167, 2249 (2004) (proposing a new regulatory framework that would
assign regulatory authority based upon each agency's regulatory expertise, a
change that would leave FDA responsible for direct health risks from
bioengineered food and drug products, but make EPA responsible for environ-
mental risks).
49. See Goldman, supra note 5, at 747-55.
50. NAS Pest-Protected, supra note 20, at 224.
51. See Goldman, supra note 5, at 751. This paper treats the herbicide uses in the
same way as the pest-protected uses without distinguishing them.
52. See J. Madeleine Nash, Grains of Hope, TIME MAGAZINE, July 31, 2000, at 38.
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D. FDA's Policy Statement on Labeling of Biotechnology in
Foods
FDA has statutory authority with respect to consumer labeling for
whole foods. FDA maintains that labeling about the use of biotechnol-
ogy in foods is not normally needed, a position that relies again on the
"substantial equivalence" of foods developed through biotechnology to
foods using traditional methods.53
1. Material Omissions and Process
FDA has the authority to prevent misleading statements in
foods, 54 and in doing so "may" take into account "material" omissions
with respect to the statements about the food or the consequences of
use.55 The FDA position has been that the method of developing a
plant through bioengineering or other plant breeding methods is not
"normally" a "material" fact that needs disclosure to prevent a food
label from being misleading.56 FDA did not call for any special label-
ing of new plant varieties merely because of the use of biotechnology.
The agency explained that it:
[H] as not considered the methods used in the development of a new plant vari-
ety (such as hybridization, chemical or radiation-induced mutagenesis, proto-
plast fusion, embryo rescue, somaclonal variation, or any other method) to be
material information .... and [the methods] would not usually be required to
be disclosed in labeling for the food. 5 7
Biotechnology was simply an extension "at the molecular level of
traditional methods."58 Since there is no showing that foods using the
new methods differ "in any meaningful or uniform way," from other
foods, or that the resulting foods present any "different or greater
safety concern," the method would not be material information need-
ing disclosure.59 Disclosure would be required, though, if there was a
need for labeling because of a safety risk such as allergenicity. Under
the policy, FDA did not find labeling to be needed for the "FlavR SavR"
tomato, one of the earliest marketed foods produced through
bioengineering, and one with an added gene derived from a tomato to
retard ripening during shipping as a way to prevent spoilage.6 0
53. See McGarity, supra note 20, at 459.
54. 21 U.S.C. §343 (2003).
55. Id. at § 321(n) (2003).




60. Id. at 22,985; Goldman, supra note 5, at 735-36 (citing FDA Press Release, at
736). FDA accepted the GRAS status of an enzyme, chymosin, produced through
biotechnology, without requiring labeling. See Direct Food Substances Affirmed
as Generally Recognized as Safe; Rennet (animal-derived) and chymosin prepara-
tion (fermentation-deprived), 21 C.F.R. 184.1685 (2004) (recognizing the safety in
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2. Food Names and Ingredient Labeling
Foods are also required to bear their common or usual name, and
ingredient labeling,61 requirements that also serve the core goal of
preventing deception. Under FDA regulations, the name used for the
ingredient used in the labeling ordinarily is specific, and not a collec-
tive or generic reference to the function, such as "sweetener" or "dough
conditioner," a specificity that can help consumers in avoiding sub-
stances to which they are allergic.6 2
FDA found that it would require a change in the name of the food
developed through biotechnology if the food "differs" from its tradi-
tional counterpart "such that the common or usual name no longer
applies" or if consumers must be alerted to a "safety or usage issue."63
While the test may seem conclusory, the context indicates the limited
circumstances in which a change in a name would be needed. FDA did
not believe that the mere use of biotechnology affected the name of the
food in a way that required disclosure. Moreover, in an example used
by the agency, FDA seemed unconcerned about the need for the name
of a food to reflect that there has been a transfer from a different
plant. FDA stated that if a peanut protein were transferred to a to-
mato, this would constitute a material fact that had to be disclosed to
prevent deception because of the need to alert consumers allergic to
peanuts, even if the "basic taste and texture" of the tomato remained
the same. 64 While the focus may have been on the need for labeling to
avoid risks from allergencity, the implication seems to be that, apart
from safety risks and a change in taste, no other labeling disclosure
would be needed.
III. STATUTORY AND CONSTITUTIONAL LIMITS ON
BIOTECHNOLOGY LABELING: LITIGATION AND
THE DECEPTION RATIONALE
The FDA policy has survived court challenges to date, and a Ver-
mont statute that required labeling for milk with a growth hormone
produced through biotechnology was struck down on constitutional
grounds. The cases, however, primarily dealt with the inadequacies of
making cheese or an enzyme derived from calf stomachs or from fermentation of
the gene for the enzyme). Since the fermented enzyme came from a gene found in
calves, and was used in making cheese, a dairy product, it does not involve a gene
transfer between species.
61. 21 U.S.C. §343(i) (2003).
62. 21 CFR § 101.4; PETER BARTON HuTrr & RICHARD A. MERRILL, FOOD AND DRUG
LAw 81 (2d ed. 1991) (reporting the agency's caution about allowing widespread
declaration of alternative ingredients in labeling since it may be a disadvantage
to consumers with allergies).




consumer demand or mere "consumer curiosity" to necessitate label-
ing. These decisions will be explored before considering the consumer
deception rationale for labeling when gene transfers are made from
different plants that affect the quality or nutritional value of the fin-
ished food, or have other significant differences.
A. Litigation on FDA's Statutory Authority and Policy
1. Litigation on Recombinant BST in Milk
FDA had found that labeling of recombinant BST (rBST) in milk
was not required since it produced "no significant effect on the overall
composition of milk" or its organoleptic properties and was not needed
merely because there was an increase in somatic cell counts.6 5 In
Stauber v. Shalala, the FDA position was challenged on the grounds
that there was a consumer demand for labeling. The court rejected
that consumer demand as a basis for disclosure when "the product
does not differ in any significant way from what it purports to be."66
Moreover, the transfer was for an agronomic use, and involved a
transfer from the same species, involving as it did use in cows of a
hormone produced by cows.
2. Litigation on General FDA Policy Statement on Labeling
In Alliance for Bio-Integrity v. Shalala, a citizen group challenged
FDA's failure to require labeling about the use of genetic engineering
in foods on the grounds that widespread consumer demand for label-
ing represented a "material" change that had to be disclosed. 6 7 The
court, though, viewed the materiality of consumer demand as a matter
left by Congress to the agency's reasonable discretion, but the court
also questioned whether that factor could ever provide the "sole" justi-
fication for labeling. Materiality is also not an independent basis for
requiring disclosures, but is, instead, relevant to the extent that a
omission is deceptive to consumers. 68
The case also dealt with the need for disclosures about gene trans-
fers from different species in the context of whether the constitutional
protections for religion required disclosures of the presence in plants
of pork or beef genes. The court upheld the agency policy in not re-
quiring these particular disclosures because the position was a neu-
tral one of general applicability. 6 9 The case for labeling of gene
65. See Stauber v. Shalala, 895 F. Supp. 1178, 1193 (W.D. Wis. 1995).
66. Id. at 1193.
67. Alliance for Bio-Integrity v. Shalala, 116 F. Supp. 2d 166, 178 (D.D.C. 2000).
68. Id. at 178; 21 U.S.C. § 321 (n) (2003).
69. See Alliance, 116 F. Supp. at 180-81. In addition, disclosure was not needed
based on the Religious Freedom Restoration Act 42 U.S.C. §§ 2000bb-2000bb-4
(2003), since voluntary labeling was an available alternative.
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transfers from different species explored below looks to a broader ra-
tionale based on consumer deception generally. The court also upheld
other aspects of FDA policy, finding that the agency's determination
that gene additions to food made through biotechnology were pre-
sumptively GRAS was within the agency's reasonable discretion.
B. Constitutional Challenge to State-Mandated Labeling for
rBST in Milk
The Second Circuit also rejected a Vermont effort to require label-
ing of rBST milk, but did so relying on the constitutional protections
for commercial speech. The statutory requirement compelling speech
was permissible only if it served a substantial government interest.
The court read Vermont's basis as aimed merely at satisfying con-
sumer demand, the consumer right-to-know, and "consumer curios-
ity," grounds insufficient to be a substantial government interest. 70
Consumer interest was insufficient to require "the functional
equivalent" of a warning when a production method had no 'discerni-
ble" impact on the final product.71
Given the court's constitutional basis, the decision limits Congress'
authority as well as that of federal agencies. What is important to
note, though, is the narrow grounds of the decision with the court re-
jecting mere consumer demand as a sufficient basis for compelled dis-
closures, a rationale that does address consumer deception as a
rationale. Again, the decision related to the use of rBST is a hormone
normally found in cows, and did not present the more complex issues
that arise with gene transfers to a food to affect its quality and nutri-
tion that come from a different plant or animal.
C. Deception Theory for Labeling
1. Deception and Food Constituents Changed by the Process
The Supreme Court's 1924 decision in United States v. Ninety Five
Barrels of More or Less Alleged Apple Cider Vinegar is often seen as
establishing that no disclosure is needed about the process of manu-
facture of a food. The Court indeed stated "[w]hen considered inde-
pendently of the product, the method of manufacture is not
material."72 On the other hand the Court found that the statute's con-
cern with preventing deception extended to "food, and the ingredients
and substances contained therein" with the aim "to enable purchasers
70. Int'l Dairy Foods Ass'n v. Amestoy, 92 F.3d 67, 73 (2d Cir. 1996). See generally
Burk, supra note 20, at 275-317 (analyzing the dormant commerce clause, and
preemption as preferable constitutional basis for faulting the state scheme).
71. Amestoy, 92 F.3d at 73.
72. 265 U.S. 438, 445 (1924).
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to buy food for what it really is."73 To determine what the food is, the
Court looked to how the food is "popularly and generally known."74
The facts of the case illuminate the Court's tough standard for when
changes alter the identity of a food.
The process involved in the case was an earlier instance of food
preservation, one accomplished by evaporating most of the liquid
from apple cider and reconstituting it later with water, after the apple
season ended, to make cider vinegar, sold as "Apple Cider Vinegar."
The Court found the name misleading since reconstituting the apples
with water meant it was not "the identical thing," as cider made with
fresh apples, the food consumers would understand the product to
be. 75 The reconstituted cider was "not the identical product" even
though it was "like or similar" to it in appearance and taste. 76
The court below had maintained that the process of evaporation
was like the mechanical separation of cream thorough a centrifuge,
and similarly needed no disclosure.7 7 The Court saw it differently,
though, apparently because the process went beyond a mechanical
change to one that affected the content of the food in a way that dif-
fered from consumer understanding of the food. Moreover, no safety
issue was found with the food, and the only objection was related to
the potential for deception. The Court left it to the producer to come
up with a new name that would not deceive by ambiguity or indirec-
tion.78 Thus, the Court did not use simply an organoleptic standard in
judging whether the name for the food was misleading, even though
that is a key test used by FDA to determine whether there is a "mate-
rial fact"7 9 that needs to be disclosed for bioengineered foods.
Biotechnology affects a food at a genetic level not in terms of a ma-
jor constituent, as occurred in theNinety Five Barrels case. Nor are
consumers familiar with biotechnology. Nonetheless, the important
question is whether the consumer would understand a food to be dif-
ferent, and not what they thought it to be, if the food incorporated a
gene from a different plant without a disclosure. An expansive read-
ing of the case permits that possibility, but its validity needs to be
tested against the implications of the test, a matter best considered, as
discussed below, in light of the examples of the changes that may be
made in foods and the type of labeling that might be provided. Of
73. Id. at 443-44.
74. Id. at 444.
75. Id.
76. Id. at 443.
77. Ninety Five Barrels of More or Less Alleged Apple Cider Vinegar v. United
States, 289 F. 181, 187 (6th Cir. 1923).
78. Ninety Five Barrels, 265 U.S. at 443-45.
79. The material fact test is in 21 U.S.C. §321(n) (2000), a provision enacted later,
but one that is best seen as an elaboration, rather than a change of the core test
for deception articulated by the Court in Ninety Five Barrels.
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course, courts often defer to the agency's judgment with respect to
what changes are material.8 0 Nonetheless, a failure to provide for any
disclosure for important transfers from different plant not only can
exceed the bounds of the agency's reasonable discretion but also be
inconsistent with providing a name that is consistent with the con-
sumer's understanding of what the food is.
IV. FRAMEWORK AND RATIONALE FOR
ADDITIONAL LABELING
The preceding discussion identified the potential legal theory for
labeling biotechnology modifications of food. This Part will consider
the need for labeling of bioengineered foods to prevent deception, be-
ginning with genetic modifications that introduce genes from different
plants to develop new plant varieties for nutrition or quality reasons.
If some type of labeling is needed for plants with genes from different
plants, consideration is needed of the test for what makes a plant dif-
ferent, including whether wide crosses beyond the reach of hybridiza-
tion should be considered to represent a different plant species.
The analysis also focuses on the discussion of the labeling needed
for foods that are found in packaged foods. Many of the foods dis-
cussed, though, are also sold as raw agricultural commodities. The
labeling in retail stores presents special difficulties, and might involve
the need for store signs or bin cards. The agency has had to develop a
format to facilitate the provision of nutrition information about pro-
duce in retail stores, and this could provide a model for other informa-
tion about produce. 8 ' While these practical aspects would need more
exploration if disclosures were considered necessary, the aim here is
to consider the underlying question, whether any disclosures are
appropriate.
A. Labeling for Gene Transfers from Different Species in
New Plant Varieties
1. Need and Labeling Format
When a food contains a gene from a different plant, it provides the
best case for finding that a disclosure of the different makeup is
needed. The theory, derived from Ninety Five Barrels, would be that
the addition of a gene from a different plant makes the food different
from the popular understanding of what "it really is." The public
would not expect a melon to contain a pineapple gene, a tomato plant
80. Alliance for Bio-Integrity v. Shalala, 116 F. Supp. 2d 166 (D.C. Cir. 2000); Chev-
ron, U.S.A., Inc. v. Natural Resources Defense Council, 467 U.S. 1227 (1984).
81. See 21 U.S.C. § 343(q)(4) (2000) (providing for issuance of guidelines on voluntary
nutrition labeling by retailers on raw agricultural commodities and raw fish and
for regulations if substantial compliance does not occur).
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a potato gene, or a strawberry a sucrose or fish gene. Moreover, the
food and its ingredients are to bear "common or usual" names that are
not deceptive, names that are typically specific.8 2
The emergence of new biotech varieties, to provide flavor or nutri-
tional benefits, serves to illustrate the issues that can arise concerning
what exactly makes a name adequate. Is it enough that the disclosure
indicates the distinctive characteristic that the new plant has, or
should it reflect that the change has been brought about by the incor-
poration of a gene from a different plant?
The development of Golden Rice can provide an illustration of how
new plant varieties developed through biotechnology should be la-
beled, assuming that the food were to be sold as a packaged food in
this country, rather than solely for use in developing countries. The
rice has a gene from a daffodil that provides both a golden color and
betacarotene that is a source of Vitamin A, an addition that has an
important nutritional benefit especially in the developing world.8 3
FDA expects the common or usual name of food to be changed to
reflect material changes, and so the would need a disclosure of the
nutritional benefit, presumably by stating the name as "rice with
betacarotene."8 4 This name, though, would not indicate that the rice
obtains the betacarotene from a different plant. More disclosure
would be needed though if consumers do not expect a food to contain a
gene from a different plant.
What is important is that the name reflects that the source is from
a different plant, and to achieve this, the name might be "Rice with
plant betacarotene."85 FDA has used the term "plants" in recognizing
a qualified health claims for Plant Sterol/Stanol Esters, thus provid-
ing an example of the use of the generic term "plant" in labeling.8 6
82. Supra note 60.
83. Nash, supra note 52, at 38, 40 (reporting genes are from daffodils and erwinia
uredovoro bacteria). Golden rice was developed at the Swiss Federal Institute of
Technology, with funding provided by the Rockefeller Foundation. Several phar-
maceutical and agribiotech companies, including Monsanto, provided free li-
censes for the intellectual property rights used in the development of the rice.
See Ingo Potrykus, The 'Golden Rice' Tale, at http://www.biotech-info.net/
GR tale.html (Oct. 23, 2000). Golden Rice is undergoing further research, with
expected completion in 2005. See http://www.syngenta.comen/social-responsibil-
ity/position.aspx.
84. The name should not be "rice", with "betacarotene" listed separately in the name
or ingredient statement, since the betacarotene is not added separately. Instead
the name needs to indicate that the food contains the betacarotene.
85. Arguably, the disclosure should refer to the specific plant source when the source
is not an edible one, which could lead to a name such as rice with daffodil-derived
betacarotene. Nonetheless, the specific reference may be confusing in suggesting
that the food has other characteristics associated with the specific plant.
86. See Health Claims: Plant Sterol/ Stanol Esters and Risk of Coronary Heart Dis-
ease, 21 C.F.R. § 101.83 (2004). Plant sterol esters include those made from edi-
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Another alternative in developing names is to use "enhanced" as
part of identifying the name of the added plant source. Thus, the
name for the rice might be "rice enhanced with plant betacarotene."
The "enhanced" term is useful in suggesting a change both in the
makeup of the food and in its effects. This enhanced designation could
also become a recognized shorthand way to indicate that an ingredient
has features that come from a different plant. Over time, for example,
consumers may be familiar enough with the "plant-enhanced" or "en-
hanced" term that it might be used at the end of the ingredient state-
ment with an asterisk to other ingredients that have such a change.8 7
The potential for development of new foods with genes from differ-
ent plants to obtain flavor characteristics also illustrates the poten-
tial for consumer confusion if the new name only reflects its flavor
characteristics. The efforts to develop sweeter melonsR8 provides a ve-
hicle for exploring the issue given the theoretical possibility for an un-
limited range of biotechnology transfers of genes whose traits have
been identified.8 9 Suppose for example that a sweet gene, perhaps one
from a pineapple or from corn, gave a cantaloupe, not a distinct taste,
but the flavor and the sweetness of the best cantaloupes.90 Should
the melon have to indicate that it had a non-melon gene? Indeed, will
any disclosure be needed about its enhanced flavor characteristics. 9 1
The key test (apart from nutrition and safety) that FDA has looked to
in determining whether gene transfer produces a "material change"
that has to be disclosed is the effect on the taste characteristics of the
ble foods and those made by esterifying byproducts of the Kraft paper pulping
process with food grade fatty acids. Id. at § 101.83(c)(2)(ii)(B)(1).
87. The development of names for the new biotech varieties could follow the model
FDA has used in the past in naming a food that was at the time unfamiliar to
consumers. In the case of canola oil for example, FDA used the technical chemi-
cal name and in parenthesis the shorter canola name that the industry preferred
to use. After several years, FDA allowed use of only canola as the name. HuTr &
MERRILL, supra note 62, at 78.
88. See David Barboza, You Asked for it, You Got It: The Pint-Size Watermelon, N.Y.
TIMES, Jun. 15, 2003, at Al (describing development without the use of biotech-
nology of a new form of watermelon through processes that have developed or-
ange bell peppers, and broccolini, a cross between Chinese kale and broccoli, and
also reporting efforts to offer "sweeter cantaloupes; smaller, better-tasting toma-
toes; and firmer peppers, some through conventional breeding methods and
others through genetic engineering").
89. Statement of Policy, 57 Fed. Reg. 22,984, 22,986 (May 29, 1992).
90. Since this flavor is all too rarely found, the example illustrates the benefits of
biotechnology; however, the question is not its benefits, but rather when it makes
a difference that needs disclosure.
91. FDA did not require labeling about the flavor advantage of FlavR SavR tomatoes
even when the company had proposed to do so, but the change came from a gene
from the same plant. See Calgene, Inc.; Availability of Letter Concluding Consul-
tation, 59 Fed. Reg. 26,647 (May 23, 1994).
2004] 1107
NEBRASKA LAW REVIEW
food, not the source of the change. 9 2 If organoleptic characteristics are
the test for significant differences, the comparison may be made to the
best of the unmodified melons, a result that might lead to no disclo-
sure. 9 3 Moreover, if the melon were simply labeled as having "better
flavor," the statement would not indicate that the source was from a
gene from an entirely different plant.
An analogy can also be made to the addition of a corn sweetener to
another food, something that would have to be listed in the ingredient
statement as a high-fructose corn sweetener. When a corn sweetener
is added to a food indirectly through a gene transfer, the sweetening
effect should be disclosed, presumably by stating that the food is
sweetened, but the source should also be disclosed, by stating that the
food is a plant-enhanced variety, or with sufficient familiarity as an
enhanced variety.9 4
2. Wide Crosses as Different
Whether a food is different is often straightforward under the pop-
ular understanding of the food: a peach is not a melon, and a tomato is
not a potato. FDA has, though, an expansive test for traditional plant
breeding. It includes not only hybridization through pollination, but
other methods such as "chemical or radiation-induced mutagenesis,
protoplast fusions [and], Embryo rescue."9 5 These more extended
techniques permit "wide crosses" to "different species" and "more dis-
tant wild relatives."9 6
As FDA has explained, "[tihe most commonly used breeding
method is a 'narrow cross', which is hybridization between varieties of
the same species. Hybridization between related species or genera
that cannot be cross-fertilized is a 'wide cross' . . . . [These] are per-
formed relatively infrequently because of technical and logistical diffi-
92. J. Howard Beales III, Modification and Consumer Information: Modern Biotech-
nology and the Regulation of Information, 55 FOOD DRUG L. J. 105, 111 (2000).
93. It may lead to a continuing evolution of the identification of the food's character-
istics. When dealing with new varieties the organoleptic test can be uncertain
and not adequately informative.
94. The enhanced variety designation is appropriate when a new form of fruit is cre-
ated such as a peach-flavored melon that combines two distinct foods possible
only thorough biotechnology, as compared with a name that only indicates a fla-
vor difference, or ambiguously suggests special quality such as peachy melon.
However, if the name is clear that it combines different foods, such as a "Peach-
Melon," the alternative enhanced variety designation would not be essential. As
a result the enhanced variety designation would not be an invariable proxy for
the use of biotechnology. But if the aim is to ensure that consumers understand
when a food has genes from a different plant, the name itself can do that by indi-
cating the different plant sources clearly.
95. Statement of Policy, 57 Fed. Reg. 22,984, 22,986 (May 29, 1992).




culties."9 7 Biotechnology may increase transfers with these related
species. If a gene transfer with a different plant needs some special
labeling indication, the determination whether a wide cross is a differ-
ent plant becomes more important.
Wide crosses can be viewed as different because of the factor noted
by the FDA: They cannot be cross-fertilized. Indeed, the FDA charac-
terizes as the "same species" only those that were possible through
narrow crosses or hybridization.98 The scientific way to determine
what a species is relates to the capacity for interbreeding, and for wide
crosses interbreeding is not possible.9 9
Some may believe that consumer understanding is not helpful in
determining whether a "wide cross" makes a food different from what
it "really is," on the grounds that consumers do not understand plant
breeding and frequently disapprove even of hybridized plants made
from conventional techniques.10 0 Hybridization though is more likely
to be familiar to the public than advanced forms of plant breeding
such as radiation-induced mutagenesis. Moreover, the test reflects a
scientific basis for identifying species.
If the wide crosses are appropriately regarded as from a different
plant, a designation such as "enhanced plant variety" would be needed
when a wide cross is made through biotechnology. As a result, if a
cantaloupe obtained a flavor gene from a watermelon, a designation
like this would be needed, even if the two fruits are distant relatives
but ones that could not be cross-fertilized. Other names are, of course
possible, so long as they are informative and not confusing and reflect
that the plant has a new component from the ordinary species. For
example, the new variety might be designed as a "wide cross," or, with
time, as an "enhanced variety."
a. Existing Wide Crosses
On the other hand, wide crosses might not be thought to be a dif-
ferent food, since there has been a continuing modification of foods
through gene transfers in various ways. Apparently a number of ex-
isting foods are the result of wide crosses made through extended
methods of plant breeding without any use of biotechnology. Thus,
"wide crosses" across species, and even across genera, [have] made use of tis-
sue culture techniques to produce genetic combinations that could not occur in
nature. The products of these techniques, including widely used varieties of
97. Premarket Notice, 66 Fed. Reg. 4706, 4710 (proposed Jan. 18, 2001).
98. See id.
99. D. PETER SNUSTAD ET AL., PRINCIPLES OF GENETICS 745-46 (1997).
100. Beales, supra note 92, at 110. The consumer understanding might also be tested
not simply in terms of approval of hybridization, but by whether a plant becomes
different if it has genes from a different species or from an ancestral plant with
which it could not be cross-pollinated.
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tomato, potato, corn, oats, sugar beets, wheat and rice, have been in use for
decades .... 101
Still, making wide crosses through these extended techniques cre-
ate important practical difficulties that limit new forms. As FDA has
noted, wide crosses "are useful for expanding the range of genetic
source material that can be introduced into food crops, but are per-
formed relatively infrequently because of technical and logistical diffi-
culties."10 2 Biotechnology makes possible as a practical matter
crosses with distant related species that may have been theoretical
but not commercially viable. Biotechnology should be regarded as
transferring genes from a different plant when they involve wide
crosses not in commercial use. 10 3 If that is not done, gene transfers
through biotechnology between a cabbage and mustard plant, its dis-
tant ancestor, might be regarded as not involving different plants, and
not needing any special identification.104
3. Varieties for Which Labeling Distinction Not Needed
Under this approach, no special labeling would be needed for plant
varieties developed through biotechnology that transfer genes from
one type of a plant to another within the species for which narrow
crosses are possible. No designation would be needed if biotechnology
techniques make possible a more efficient transfer of genes that could
be made with traditional plant breeding through hybridization for
that plant species. Biotechnology that transferred genes possible only
with wide crosses would need to be designated, unless perhaps it mir-
rored what is already done in plants that are already commercially
grown. To have a realistic benchmark for what makes a plant differ-
101. Id. at 106. See discussion supra note 88 for the development of broccolini. See
also Food Labeling; Foods Derived from New Plant Varieties, 58 Fed. Reg.
25,837, 25,840 (Apr. 28, 1993) (stating that "most commercially produced toma-
toes have introduced genetic traits derived from related weedy species.")
EPA regards "wide crosses" as part of the definition of conventional plant
breeding for purposes of plant pesticides. See 40 C.F.R. pt. 174.3 (2003); Regula-
tions Under the Federal Insecticide, Fungicide, and Rodenticide Act for Plant-
Incorporated Protectants (Formerly Plant-Pesticides), 66 Fed. Reg. 37,772,
37,795 (July 19, 2001).
102. Premarket Notice, 66 Fed. Reg. at 4710.
103. The existing wide crosses in use at this point should be accepted or grandfathered
as within the plant type because of its acceptance in practice. New plant vari-
eties that represent wide crosses that are developed without biotechnology would
need a name that adequately indicated that it combined different plant forms.
For example, if broccoli and cabbages represent wide crosses, a new hybrid ver-
sion combining them and called Broccage would have a name adequate to indi-
cate the different plant sources. If the name were ambiguous, a designation of
"advanced variety" would be appropriate to avoid confusing consumers who asso-
ciate the enhanced variety term especially with the use of biotechnology.




ent, cross-fertilization provides the surest test, extended if at all only
to reflect the wide crosses developed through extended methods that
were sufficiently viable to come into general use.10 5
4. Transfers from Animal Species: The Need for Labeling
Specific labeling of the source of a gene is needed when there are
major differences in the species involved. Theoretically, a gene from a
flounder might be used in a tomato or strawberries to provide protec-
tion from frost.106 Some might find any labeling unnecessary, regard-
ing it as only the use of a process that needs no disclosure when the
taste of the food is not altered. 0 7
However, this gene transfer involves the introduction into a plant
of a fish gene, something that not only crosses a species line, but the
flora/fauna biological categories. The difference simply seems too
great, and one that should be considered misleading unless disclosed
because it differs so basically from the consumer understanding of
what a food is. If a change were made, for example, to affect a food's
crunchiness, a designation should be made under the policy discussed
above that reflects the non-plant, such as "fish-enhanced crunch."
Complications arise, though, when an animal/plant gene transfer
involves an agronomic use. The field test that occurred with a flounder
gene was to protect the tomato from frost, not specifically to affect the
flavor of the finished food. This use might be thought to be like pesti-
cide and growth promotion uses for which labeling is not provided.
Even if no additional labeling is considered necessary for these other
forms of agronomic uses, when the transfer involves a transfer of an
animal/fish gene to a plant (or to a different animal or fish) the change
affects consumer understanding of the food in a way that needs disclo-
sure. Thus, even if the use is considered agronomic, the labeling
should indicate the presence of a flounder gene in a plant, perhaps in
the ingredient statement as "fish-enhanced crop protector."
105. New forms of corn are being developed, through 'conventional means," that have
a gene for Vitamin A that comes from other varieties of corn. Whether these new
forms would need special labeling under this proposal would be affected by
whether they reflect wide crosses or narrow crosses. See Andrew Pollack, Grant
Aims at More Healthful Crops, N.Y. TIMES, Oct. 21, 2003, at F7.
106. See Statement of Policy, 57 Fed. Reg. 22,984, 22,986 (May 29, 1992) (noting that
"[recombinant DNA techniques involve the isolation and subsequent introduc-
tion of discrete DNA segments containing the gene(s) of interest into recipient
(host) plants. The DNA segments can come from any organism (microbial,
animal, or plant)").
107. Labeling has been seen as unnecessary because some genes found in animals are
also present in plants and the animal gene may be the most convenient source of
a protein that is also found in plants. Beales, supra note 92, at 110. The result-




This labeling would also indirectly benefit consumers who have
special labeling interests. Some consumers are vegetarian and may
find unacceptable the presence of a non-vegetable constituent even in
the form of a gene, which only expresses agronomic characteristics
useful for growth. This type of labeling suggested here would indicate
the presence of an animal gene in plants on the grounds that it is
needed in view of the general consumer expectations about the vegeta-
ble nature of a plant. The labeling may also be of interest to those
with religious objections to consuming beef or pork constituents. A
court has rejected the constitutional or statutory necessity for provid-
ing special labeling solely to meet religious preferences.OS The ratio-
nale for the labeling suggested here is broader and rests on the need to
prevent misleading the general consumer who does not expect meat or
fish derived substances to be in a plant unless disclosed.109
B. Plant Biotechnology for Pesticide Use and Labeling
As already discussed, many examples of biotechnology in plants re-
late not to food quality but to pest protection. Corn and soybeans con-
tain biotech plant-incorporated protectants, which leads to the
presence of biotech gene transfers in many processed foods.11o The
case for providing any labeling on foods about pesticide uses, chemical
or biotech, faces serious obstacles. These obstacles relate to the decep-
tion connection, the relevance of labeling exemptions for chemical pes-
ticides, and constitutional restraints and practical difficulties. Before
discussing the difficulties, the impact of developments in biotechnol-
ogy need to be noted. The discussion also seeks to identify options
that can address some of the labeling hurdles.
1. Impact of Biotechnology on Need for Labeling
The absence of labeling on the biotech pesticides may become more
problematic, if labeling were to be provided, as suggested here, for
quality changes in foods made through gene transfers from different
plants. If a tomato were developed with a potato gene to achieve a
quality effect, the tomato would have to be designated in some way to
indicate the addition such as "plant-enhanced," under the scheme sug-
108. Alliance for Bio-Interity v. Shalala, 116 F. Supp. 2d 166, 179-80 (D.C. Cir. 2000)
(holding that the right to free exercise of religion is not violated by government
allowing unlabeled genetically engineered foods on the market).
109. Id. The special restriction on consumer labeling for pesticides as chemical pre-
servatives, discussed supra in Part II, should not preclude this disclosure. The
statute was aimed at protecting the use of chemical pesticides, not animal
sources. Even if the exemption is read to cover pest protectants made through
biotechnology, that policy should not go so far as to encompass animal sources
used in plants.
110. CORNEJO, supra note 3.
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gested above. No such designation is made now, if the tomato had a
potato gene to protect against insects. Additions made through bio-
technology for agronomic purposes are different from the chemical
pesticide uses that are made through separate appreciation in the
field. Instead the change occurs at the genetic level in the seed before
the seed is planted and occurs through a similar process whether the
change is for an agronomic purpose or for a food's quality or nutrition.
Consumers may believe labeling about the presence of a plant from a
different species in a food, will cover all additions to the food, includ-
ing those for agronomic uses for pest control as well as quality. If they
did so and relied on the absence of the labeling as indicating there
were no additions from other plant sources, they could be misled.
The potential for confusion could be alleviated if consumers under-
stood that the special labeling does not apply to agronomic uses, but
that distinction may not be clear to many. Moreover, if no labeling
appears on agronomic uses, it will heighten the importance of the clas-
sification of a use as an agronomic, and whether they encompass dual
uses or other forms of farm use such as frost protection.1 1 1
2. Form for General Labeling
An approach to the labeling conundrum explored here would be for
Congress to require any plant using chemical or biotech pesticides or
herbicides to be labeled at the end of the ingredient statement as
"Crop Protectors" or "Enhanced and Other Crop Protectors" with the
enhanced term being an indicator that a transfer from different spe-
cies was made to the food crop. The disclosure would be for any pesti-
cide functional use and would not specify the means used.112 The
general labeling would state the positive effect of the use, and might
not encounter the resistance that there may be to the "chemical" des-
ignation. But the statement would alert consumers in some way that
the agronomic uses introduce residues or a different substance into an
ingredient to kill plant pests. If consumers do not expect foods to con-
tain genes from different plants, or chemical residues, for agronomic
purposes, this statement helps to guard against deception. Moreover,
the consumer would then be able to seek more information from the
food manufacturer about more specific type of pest or crop protector
111. For example, the FlavR SavR tomato, discussed supra at note 91, used a gene
transfer to delay ripening and spoilage during shipping. Perhaps some might
characterize that as a pest-related use or preservative use when the gene came
from a different plant.
112. The disclosure would be broad enough to cover Bt sprays used in organic agricul-
ture, but organic foods could have labeling that crop protectors meet the stan-
dards for organic foods. See Bratspies, supra note 48, for organic use, and 7
C.F.R. § 205.602 (2004) for absence of Bt sprays from non-synthetic substances
prohibited from use in organic agriculture.
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used. This can create a market incentive for more voluntary
labeling.113
C. Objections to Labeling and Assessment
1. Absence of Deception
Some may see no risk of deception since consumers do not expect
foods to be pesticide-free and would recognize, with reflection, that ag-
ronomic practices are not a matter of labeling. The long history of the
absence of pesticide labeling would be seen as dispelling any notion of
consumer deception on this matter.
2. Insufficiency of General Labeling
On the other hand, some may find the general labeling as too in-
nocuous and uninformative for consumers. Some may favor instead
discrete labeling that specifically identifies foods that use
biotechnology.1 1 4
3. Limits on FDA's Authority, and Labeling Exemption for
Pesticide Chemicals
FDA is precluded by statute from requiring pre-harvest agronomic
uses of chemical pesticides to be labeled as "chemical preservatives,"
an exemption that arguably may carry over to the biotech pest protec-
tors. Consequently a Congressional authorization of labeling for pesti-
cide uses would be important in establishing the agency's authority
and in avoiding litigation. Moreover the history of the exemption il-
lustrates the practical and policy issues involved.
a. History
Foods are required to declare the presence of chemical preserva-
tives.ln 5 In the 1950s, FDA sought to require labeling on store display
bins stating that the food bore a "chemical preservative" when foods
had pesticide chemicals applied after harvest. FDA believed that con-
sumers are "entitled to know" and "want to know" whether a food con-
tains a preservative.1 1 6 FDA also believed that pesticides applied
113. See infra note 155 for FDA policy on voluntary labeling, and Section IV.D. on
environmental aspects that arguably might influence consumer decisions. For a
means for consumers to obtain more information, see Emily Robertson, Finding a
Compromise in the Debate Over Genetically Modified Food: An Introduction to a
Model State Consumer Right-to-Know Act, 9 B.U. J. Sci. & TECH. L. 156 (2003).
114. McGarity, supra note 20, at 502-03.
115. 21 U.S.C. § 343(k) (2000).
116. Goldman, supra note 5, at 741 (citing Chemical Preservatives: Hearings on H.R.
9521 Before a Subcomm. of the House Comm. on Interstate and Foreign Com-
merce, 85th Cong. 2d Sess. 118 (1958) (statement of John L. Harvey, Deputy
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after harvest, but not before, were ingredients to the food subject to
ingredient labeling absent an exemption.iX7 However, Congress ob-
jected because of practical factors and the risk of "buyer resistance,"
and in 1960 made "chemical preservative" labeling inapplicable to pes-
ticide chemicals used before harvest.X18 Moreover, labeling about the
use of pesticides after harvest was limited to a disclosure on the ship-
ping container (as an aid to agency enforcement of tolerance levels),
and would not cover display in the store.1 19 While FDA "in principle"
still believed in the need for labeling, the agency accepted the legisla-
tive compromise recognizing the enforcement difficulties at the federal
level and the prospects for prolonged litigation.120
b. Wider Applicability of Policy?
The objections to labeling for use of pesticide chemicals have been
seen as ones that strongly resemble the dispute over the labeling of
genetically-modified foods.121 The industry emphasized the practical
problems in providing labeling about pesticides, including the cost in-
volved of segregating foods for labeling, and the difficulty of determin-
ing when commingled foods had been treated. Furthermore, since the
same pesticide may be used before harvest and after harvest, the in-
dustry maintained successfully that they should be treated the same
way for labeling with none provided to consumers for either use.122
Since plant-incorporated pest protectants, the ones produced by
biotechnology, are regulated by EPA as "pesticide chemicals," the
same preclusion of labeling has been seen as appropriate for biotech
Commissioner of Food and Drugs, FDA, Dept. of Health, Education, and
Welfare)).
117. Letter from Acting Secretary Elliot Richardson to Senator Lester Hill (Sept. 11,
printed in S. Rept. 1548, 86th Cong. 2d Sess. 5 at 6 (1960)) [hereinafter Richard-
son Letter]. The agency rationale was that when pesticides are applied after har-
vest, the fruit or vegetable "being no longer in its natural state, is a 'fabricated
food' and the chemical is an 'ingredient.'" Id. This rationale for ingredient label-
ing would not apply to pesticides used before harvest. Interestingly, FDA regards
bioengineered foods as containing an "added" substance for food safety purposes,
if not for ingredient labeling. Statement of Policy, 57 Fed. Reg. 22,984 (May 29,
1992).
118. 21 U.S.C. § 343(k) (2000) now exempts from labeling as a chemical preservative
"a pesticide chemical when used in or on a raw agricultural commodity which is
the produce of the soil." The agency also had authority to establish safety levels
for pesticides, which reduced the need for labeling. H.R. Rep. No. 85-2119, at 6
(1958).
119. The disclosure can now be required on shipping containers of foods for which pes-
ticide chemicals have been applied after harvest, but not while on the containers
held for sale in stores. 21 U.S.C. §343(1) (2000).
120. Richardson Letter, supra note 117.
121. Goldman, supra note 5, at 742.
122. Id. at 743.
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products as well as chemical ones. 123 The history could also be read
as confirming the soundness of FDA's position that the process of
manufacture is not relevant for labeling purposes at least for pest-re-
lated agronomic uses. Indeed, FDA maintains that the "labeling pro-
hibition pertaining to postharvest pesticides applies to preharvest
pesticides since the same type of labeling problems would be encoun-
tered."12 4 In view of the problems, the agency stated, in 1991, that it
was "not prepared to seek statutory authority to require pesticide la-
beling at this time."125
Perhaps one can read the Congressional limits narrowly as limited
to chemical pesticides, and solely concerning labeling about the pres-
ence of a "chemical preservative," a term especially likely to draw con-
sumer resistance. Any reading, though, which led to labeling solely
for biotech pesticides has the consequence of putting them at a disad-
vantage and may confuse consumers if they think unlabeled foods con-
tain no pesticides. Moreover, any such interpretation would likely be
one that the court viewed as committed to agency discretion, and an
expansive approach by the agency seems doubtful.126 Consequently,
any change in labeling for biotech pest protection is likely to have to
come from Congress. In developing a legislative proposal, it will be
important to be mindful of the practical objections and compliance
problems that influenced Congress and the agency in the past.127
4. Assessment of General Labeling Approach
The type of general labeling outlined above has some advantages
in dealing with the practical obstacles that have been concerns for
Congress and others. Agricultural crops like corn and soybean are
shipped as commodities, which makes specific disclosures about pesti-
cide use difficult, but which may not necessarily rule out more general
labeling. There is no burden of segregating crops when all have to
bear the same labeling. Since virtually all crops use some type of pes-
ticide, the designation would presumptively be needed for all and
could appear in the same way for all. Still, implementing such an ap-
123. Id. at 740.
124. Food Labeling: Declaration of Ingredients, 56 Fed. Reg. 28,592, 28,611 (June 21,
1991).
125. Id.
126. In 1991, for example, the agency not only found it lacked the authority to require
labeling for pesticide residues in foods, but also declined to seek a legislative
change, citing the practical difficulties and enforcement problems in detecting
residues. See id.
127. See also NAS ANIMAL BIOTECHNOLOGY, supra note 7, at 118, Box 7.2 (noting the




proach may involve developing detection methods to ensure enforce-
ment, and the recognition of an exemption for low-levels of use. 128
A labeling requirement that applied only to biotech forms of pesti-
cides could indirectly provide an advantage for use of chemical pesti-
cides. The chemical pesticides have their own detriments for the
environment, 129 and some believe the agronomic uses of biotechnology
have environmental advantages. 130 The general labeling outlined
above would apply to both types and not advantage either type. The
labeling could either simply refer to crop protectors or to both types,
by saying "enhanced or other crop protectors."
Overall, labeling that reflects when biotechnology introduces a new
species into a food used for quality purposes but not agronomic pur-
poses has a potential for consumer confusion that warrants reconsid-
eration of the labeling about agronomic use. Developing an adequate
response, however, presents considerable hurdles. While the general
disclosures, suggested above has promise, further study is warranted
of other alternatives.
In any case, if biotech pesticides are used solely, or in part, to pre-
serve the finished food, a label declaration should be made. Chemical
preservatives added to a processed food require a label declaration. 13 1
A comparable disclosure, with an appropriate name, is also needed
when bioengineering permits an addition to a food that achieves a
substantially equivalent preservative function. Indeed, this need for
equivalent treatment provides an alternative explanation for the rea-
son for disclosures of the use of irradiation in finished foods, a process
that substitute for other form of adding a preservative to a food.132
128. See id; McGarity, supra note 20, at 502 (citing European Union exemption from
its labeling requirements of foods with less than 1% of genetically-modified
material).
129. See Goldman, supra note 5, at 760 (suggesting biotech pest protectors, while not
perfect are "'examples of the approach'" Rachel Carsons advocated as an alterna-
tive to chemicals in dealing with disease resistance) (citing Bernard Dixon, The
Paradoxes of Genetically Modified Foods, 318 BRIT. MED. J. 547, 548 (1999).
130. Jonathan Rauch, Will Frankenfood Save the Planet, ATLANTIC MONTHLY (Oct.
2003), available at http://tehatlantic.com/issues/2003/10/rauch.htm (noting ad-
vantages of salt-tolerant and no-till farming from biotech varieties).
131. 21 U.S.C. § 343(k) (2000).
132. See Fred H. Degnan, Biotechnology and the Food Label: A Legal Perspective, 55
Food & Drug L J. 301 (2000) (noting irradiation as a unique example of the disclo-
sure of a process, and examining the extent to which changes in food composition
or consumer safety concerns provide an explanation). Irradiation constitutes a
food additive by law. 21 U.S.C. § 321(s) (2000).
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D. Animal Biotechnology and Labeling
1. Growth Promotion and Emerging Uses
Animal biotechnology involves important uses, ones that could
have labeling implications.133 The emerging uses involve a range of
novel issues, including the cloning of animals for food production.13 4
The NAS Committee that evaluated the emerging uses found no "sci-
ence-based" reason for labeling, but it recognized there might be
"other reasons" that might provide a legitimate basis in public policy
for requiring labeling."135 The reasons included that "arguably... in
the current climate surrounding biotechnology, the fact of genetic en-
gineering is an aspect of the identity of the food."136 Because the
wider policy concerns were beyond the Committee's charge it did not
make recommendations. An exploration of these issues is also beyond
the reach of this paper. Instead the focus will be on the relevance of
labeling with respect to the farm-raised salmon.
The farm-raising of salmon creates changes in the salmon, even
apart from biotechnology, that can bear on labeling. Artificial colors
have been added to the salmon, a practice which has been challenged
as necessitating labeling about the addition of artificial color. 137
Farm-raising also affects the nutritional profile of the salmon. They
are larger and have more fat and fewer Omega-3 fatty acids than wild
salmon, 138 and they may have higher PCB levels, ones that can reflect
higher contamination levels in Europe as compared to North and
South America.139 Perhaps some means to provide a disclosure about
the nutritional difference should be considered.
133. If consumers expected an animal's substance to come from what an animal eats
without being enhanced by drugs, labeling of the food to indicate growth enhance-
ment produced by the use of animal drugs may be needed. Comparable labeling
would also be needed for antibiotics and other animal drugs that promote growth.
The change would be so substantial, though, that Congressional action would be
appropriate.
134. See NAS ANIMAL BIOTECHNOLOGY, supra note 7, at 118 Box 7.2.
135. NAS ANIMAL BIOTECHNOLOGY, supra note 7, at 118 Box 7.2.
136. Id. The other reasons included religious, ethical, right-to-know or preference
reasons.
137. The farm-raised salmon have a greyish color, because of the absence of crus-
taceans in their diet. Marian Burros, Issues of Purity and Pollution Leave
Farmed Salmon Looking Less Rosy, N.Y. TIMES, May 28, 2003, at Fl. The grow-
ers, ever resourceful, have added artificial colors to achieve a better tint, a prac-
tice that led to a class action suit alleging that the failure to label the food as
containing artificial colors violated federal law. See 21 U.S.C. §343(k). As a re-
sult stores are re-labeling the foods. If the fish were ever bioengineered to add a
suitable color from a carrot gene or from a shrimp gene, it would create a nice
maze of labeling issues.
138. Burros, id. at Fl.
139. Id; Marian Burros, Farmed Salmon is Said to Contain High PCB Levels, N.Y.
TIMES, Jul. 30, 2003, at F1 (describing report from Environmental Working
Group, and noting that while the PCB levels do not exceed FDA guidelines, the
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2. Species Impact and Salmon
a. Scientific Issues
The principal focus here is on the potential for animal biotechnol-
ogy to impact the species as illustrated by a pending proposal that
affects salmon. Biotechnology permits the addition of a gene to
salmon that expresses a growth hormone and which allows develop-
ment of a transgenic line to be used in farm-raised salmon.140 In fish
farming generally, some salmon escape from the pens and can breed
with wild salmon. The very large salmon made possible by the growth
hormone gene transfer creates an environmental risk that escaped
salmon could interbreed with the wild salmon, altering the species.141
Similar risks can occur with respect to other types of transgenic fish
that are farm raised.
A National Academy of Sciences Committee that evaluated Animal
Biotechnology for FDA found that sufficient "gaps still exist in our un-
derstanding of the key net fitness parameters to allow an assessment
of the impact of [Genetically Engineered Atlantic salmon] into the
wild."142 Some of the lines of transgenic salmons in laboratories grew
four to six times faster than non-transgenic salmon.143 The Commit-
tee found there is an environmental concern that "cannot be dis-
missed" about whether the salmon and other transgenes could result
in new evolutionary lines because "the magnitude of phenotypic
change that is possible with transgenesis could exceed that of conven-
tional breeding or natural mutations."144 According to the report:
At the heart of the issue is how species evolve. Domestication is widely be-
lieved to be the consequence of small incremental changes in trait value, and
the ecologic niche of the animal is not changed if the phenotype of a mutant
individual is only slightly changed. Expression of transgenes, however, could
cause mega-mutations that instantaneously and substantially change the
phenotype of the transgenic organism. 145
agency might reexamine the guidelines); see also Ronald A. Hites et al., Global
Assessments of Organic Contaminants in Farmed Salmon, 303 Science 226, 229
(2004) (demonstrating "the importance of labeling salmon as farmed and identify-
ing the country of origin.").
140. For a description, see NAS ANIMAL BIOTECHNOLOGY, supra 7, at 89-92.
141. Id. at 11; see also Kenneth R. Weiss, It Came From the Gene Lab; Faster Growing
Salmon?, L.A. TIMES, May 14, 2003, at Al; Marian Burros, Chefs Join Campaign
Against Altered Fish, N.Y. TIMES, Sept. 18, 2002, at Fl.
142. NAS ANIMAL BIOTECHNOLOGY, supra note 7, at 11. The Committee also noted
transgenic salmon that grow faster because of a growth hormone could provide an
environmental benefit by producing less waste. Id.
143. Id.
144. Id. at 79-80.
145. Id. at 80.
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The environmental risks from animal biotechnology, in general, has
been seen by the Committee as "the greatest science-based concern"
with animal biotechnology. 14 6
b. FDA's Statutory Authority with Respect to Environmental
Impacts
FDA has the authority to regulate the genetic addition of a growth
hormone to the salmon under its authority over animal drugs. 147 Im-
portant questions exist, though, about FDA's authority to regulate the
transgenic fish based on an environmental impact, and about the
agency's institutional capability to deal with the environmental
questions.148
FDA, though, maintains that it has the authority to consider envi-
ronmental effects. 149 On the other hand, the agency "has not taken an
action in which it has identified an environmental effects not involv-
ing risks to human health as an influential consideration."15o FDA,
though, took an expansive view of the way in which safety risks are
created when it banned the use of chlorofluorocarbon (CFCs) in FDA-
regulated products, and required a warning as an interim measure. 15 1
The CFC's in the stratosphere depleted the ozone layer and increased
the risk of skin cancer to humans. Thus the safety risk was not to the
immediate user and came about indirectly.
In determining whether to approve an animal drug, FDA considers
not only the safety to humans but also the safety to animals, with the
146. Id. at 9.
147. See discussion supra, Part II.
148. NAS ANIMAL BIOTECHNOLOGY, supra note 7, at 111, 113-15; see also Future Fish,
supra note 43, at 47-49, 57; discussion supra Part II; FDA Questions and An-
swers about Transgenic Fish, at http://www.fda.gov/cvm/index/consumer/trans-
gen.htm.
149. Study Faults U.S. on Assessing Altered Fish, N.Y. TIMEs, Jan. 15, 2003 at A16
(citing FDA official that the agency requires environmental assessments on
animal drugs and can seek input from other agencies). In the 1970s, a court
found that the National Environmental Policy Act provides FDA with "supple-
mentary authority" and permits FDA to base a decision upon environmental fac-
tors, when balanced against other relevant considerations. Envtl. Defense Fund,
Inc. v. Mathews, 410 F. Supp. 336, 338 (D.D.C. 1976).
150. See HuTr & MERRILL, supra note 62, at 1311; Future Fish, supra note 43, at 48.
151. See 21 C.F.R. § 2.110 (1979) (ban citing the risks of increase in skin cancer and
changes in the climate); 21 C.F.R. § 740.11 (1979) (warnings on cosmetics). FDA
has since revised its regulation to provide that the labeling requirements are des-
ignated by the EPA, 21 C.F.R. 2.40.11 (2003). The agency also now uses its au-
thority under the Clean Air Act for determining essential uses, but has stated
that a nonessential product may still be considered adulterated or misbranded
under the food and drug laws. Final Rule, Use of Ozone-Depleting Substances:
Essential Use Determinations, 67 Fed. Reg. 48370, 48372 (2002). The author
provided advice to the agency with respect to these regulations. The regulations
were not challenged in court.
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target animal being the focus.152 Perhaps an expansive view of the
safety risks to the animals could encompass the indirect harm to the
wild form of the same species. Still, the questions raised about the
scope of the agency's authority are important ones, and legislative ac-
tion to provide clear authority would remove litigation risks that may
arise if the industry had major objections to the agency action.
c. Role for Consumer Labeling
Assuming that FDA's statutory responsibilities reach these envi-
ronmentally-caused effects, another question arises about the extent
to which consumer labeling should play a role. Assume, for example
that FDA approves the use of growth hormone, viewing the risk as
limited when farm operators use safeguards to prevent escape. Still,
according to the NAS Report many uncertainties remain, and contin-
ual monitoring may be appropriate. 15 3
Given the uncertainty consumer labeling has a role. While there is
no transfer of a gene from a different species, the transfer has an im-
pact on the species itself. A disclosure can be viewed as needed to
prevent deception since consumers would not expect that their con-
sumption. of a food like salmon to pose a risk that the wild form of the
food would be altered. That disclosure might, for example, be in the
form of a statement that requirements are in place to reduce and mon-
itor the risk of escape of farm-raised salmon that could adversely af-
fect the wild salmon.
Consumers are in a special position to evaluate the risks from
transgenic salmon. The growth enhancement produced by biotechnol-
ogy lowers the cost and increases the availability of a food that con-
sumers desire for its health benefit and flavor. On the other hand, the
enhanced salmon can pose a risk of environmental harm to the wild
form, one that it may not be entirely possible to eliminate. The trade-
off in how to balance the risks and benefits is a difficult one, and one
that should not necessarily be made solely at the regulatory level on
an all-or-nothing decision when the extent of the risk depends upon
practical developments. Consumers have their own responsibility to
monitor how effectively the environmental risks are balanced against
their personal interest in availability. Providing labeling about the
effect of enhanced growth effects is one way to involve consumers in
the choice. Some may decide to not use the salmon that poses the risk.
Others may look for foods labeled as having extra safeguards against
escape of the salmon that exceed any restrictions that are governmen-
tally imposed. Consumers may take special interest in reports of vio-
152. Future Fish, supra note 43, at 48.
153. See NAS ANIMAL BIOTECHNOLOGY, supra note 7, at 115 (stating "uncertainties
remain about the efficacy of various containment measures and what degree of
efficacy is appropriate or acceptable in various circumstances").
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lations of restrictions, an interest which may lead to better
compliance. The labeling could create a market in developing new
ways to minimize the risk.
Voluntary labeling by producers, though, is often seen as the ap-
propriate alternative to mandated consumer labeling about the use of
biotechnology. 154 On the other hand, if consumers do not know of the
risk of species harm that may occur with transgenic salmon, they will
not know of the significance of additional measures. If the labeling is
provided it may lead to the provision of additional voluntary labeling
to consumers as discussed above, but that labeling presents its own
complications. FDA has provided guidance on voluntary disclosures,
and while it objects to claims like "GM free," it accepts as appropriate
statements like "We do not use ingredients that were produced using
biotechnology."155 The affirmative statements also need to avoid mis-
leading implying safety risks from the use of biotech, but there can be
tough questions about what is misleading, an issue that has led to
private litigation. 156 While an appropriate format will need to be
worked out, labeling remains an appropriate way to inform consumers
when a particular use of biotechnology may alter the natural species
of the food, and to permit them to seek alternatives to reduce the spe-
cies risk.
3. Environmental Risks from Bt Pesticides in Crops
While the use of transgenic fish provides a dramatic example of a
potential species impact, some pesticide uses of biotechnology may
also present environmental risks to the traditional means of pest con-
trol. The gene transfer of the soil bacterium Bt to corn to control
pests, for example, can erode the effectiveness of the use of Bt in or-
ganic agriculture as a temporary spray by contributing to pesticide
resistance. 15 7 The EPA and the Department of Agriculture share re-
154. Beales, supra note 92, at 112-13.
155. Draft Guidance for Industry: Voluntary Labeling Indicating Whether Foods Have
or Have Not Been Developed Using Bioengineering; Availability, 66 Fed. Reg.
4,839, 4,840 (Jan. 18, 2001). But see McGarity, supra note 20, at 463-64 (discuss-
ing criticisms that the guidance could discourage voluntary statements).
156. See David Barboza, Monsanto Sues Dairy in Maine Over Label's Remarks on Hor-
mones, N.Y. TIMES, Jul. 12, 2003, at C1 (describing lawsuit by Monsanto alleging
that the dairy's milk carton labeling that there are no artificial growth hormones
in the milk is deceptive and misleading); Monsanto Co.: Oakland Dairy Settles
Lawsuit over Growth Hormone Labeling, WALL ST. J., Industrial Brief, Dec. 26,
2003, available at 2003 WL-WSJ 68131889 (reporting a settlement with confiden-
tial terms under which the label could state "No Artificial Growth Hormone
Used," along with a message that FDA has found no significant difference in milk
from growth hormones; the prior labeling did not include "used").
157. Rebecca Bratspies, supra note 48, at 307, 320 (describing transgenic Bt crops as




sponsibilities to ensure that farmers who use the biotech form of Bt
maintain surrounding reserve areas of non-use to retard the develop-
ment of Bt resistant pests.158 The adequacy of the system and its
monitoring have been criticized, and a recommendation has been
made for a new regulatory framework with coordinated or central de-
cision making. 159
Whether consumer labeling can play any role in dealing with an
environmental impact like that involving the use of Bt to control pests
is problematic. There is no identifiable impact on a specific food, as
there is with transgenic fish. Questions exist about FDA's authority
to regulate environmental risks created by animal drugs, an area in
which the agency has direct responsibility. The responsibility for the
risks from pesticides is placed elsewhere. Of course, if consumer label-
ing for foods had a general disclosure about the use of "crop protec-
tors," it may have some usefulness for consumers who want to take
environmental considerations into account.
V. CONCLUSION
The development of new forms of foods from biotechnology has the
potential to provide consumers with nutritional benefits they desire
and more interesting and flavorful forms of food. On the other hand,
the scope of the ability to make novel foods raises the specter that
consumers may distrust the use of biotechnology in foods, and even
regard some of them as "Frankenstein Foods," as European consumers
have done.
The labeling for the new foods can be expected to reflect the quality
and nutritional changes produced. However, when the change comes
about through a transfer to a food of a gene from a different species,
not possible through traditional plant hybridization, the change tests
the understanding of what the food is. If consumers come to believe
that foods have undisclosed "secret" genes from other plants, it could
create a crisis of confidence like that created by the StarLink(R) inci-
dent, when corn intended only for use in animals was found in
tacos. 160 The best approach to preventing consumer deception is to
have the labeling reflect in some way when a common food contains a
gene from a different species that affects its characteristics. The use
of the designation "plant-enhanced" or "enhanced" is a way to do that,
one that takes account of some of the practical problems of labeling.
158. Id. at 323-29.
159. Id. at 347-48; see Editorial, Keeping Seeds Safe, NEW YORK TIMES, Mar. 1, 2004,
at A20 (commenting on the need for vigilance in protecting traditional seed stocks
- the "genetic reservoir of plants on which humanity has depended for most of its
history" - in light of a study finding contamination with genetically modified va-
rieties in half the samples tested of traditional corn and soybean).
160. For information on StarLink, see McGarity, supra note 20, at 485-87.
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When the transfer crosses the plant/animal biological line, the name
should reflect with specificity the type of transfer involved.
Biotechnology can also involve transfers from different species for
pest control or growth promotion. No consumer labeling has been pro-
vided for these agronomic uses, as a result of practical considerations
and legal questions. Consumers could be confused, though, if the use
of biotechnology is disclosed when a transfer from a different plant
occurs for quality reasons, but not for pest control. Some reconsidera-
tion is needed about these different approaches to labeling, including
requiring a label designation on foods grown with chemical or biotech-
nology pest protectors, indicating that "crop protectors" have been
used. Legislative action should be considered if the agencies do not
adapt the recommendations made here.
Biotechnology can have a species connection in another way, as il-
lustrated by the development of farm-raised salmon with a gene for
enhanced growth. The transgenic salmon may escape and interbreed
with the wild salmon in a way that alters the species. A disclosure to
consumers of this risk would make them aware of a larger harm that
they would not expect. They could participate in making the balance
between risks to the species and the health and economic benefits to
the user that come from the expanded availability of the salmon.
Some may question Congress' or the agency's constitutional au-
thority to require a disclosure about the impact on the wild species as
a way to inform consumers and to involve them in reducing and moni-
toring the risk.16 1 If the grounds for the labeling were only to satisfy
consumer curiosity, the adequacy of the Government interest would be
insufficient. The core basis, though, for all the labeling requirements
explored here is the need to prevent consumer deception, an interest
recognized as a substantial one that can justify the regulation of com-
mercial speech.16 2 A disclosure about gene transfers that leads indi-
rectly to an alteration of the wild species can appropriately be seen as
deceptive. A Congressional and regulatory judgment about the new
ways that deception can occur through the emergence of biotechnol-
161. Int'l Dairy Foods Ass'n v. Amestoy, 92 F.3d 67 (2d. Cir. 1996).
162. See Central Hudson Gas & Elec. Corp. v. Pub. Serv. Comm'n of N.Y., 447 U.S.
557, 561-64 (1980) (holding First Amendment protects commercial speech if it is
not misleading); Zauderer v. Office of Disciplinary Counsel of Supreme Court of
Ohio, 471 U.S. 626, 673 (1985) (holding that disclosure requirements do not in-
fringe on an advertiser's First Amendment interests if "reasonably related to the
State's interest in preventing deception of consumers."). Still, speech restrictions
are not permitted if they are more extensive than necessary to achieve the gov-
ernment's interest, and an adequate showing would be needed that the direct
regulatory restrictions to prevent release of the salmon were not themselves
enough. Thompson v. Western. States Med. Ctr., 535 U.S. 357 (2002)
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ogy, and the reasonableness of disclosures as a response, should be
regarded as one that lies within the legislative judgment.16 3
The use of biotechnology in foods involves major challenges, includ-
ing determining when changes affect the consumers' understanding
about what a food is. Developing an appropriate means to label new
foods under old principles warrants continued academic analysis. The
important point is that adequate disclosures are needed to prevent de-
ception and to permit the food industry to retain the confidence of
consumers.
163. See Thompson, 535 U.S. at 389 (Breyer, J., dissenting) (opposing an overly rigid
commercial speech test and recognizing Congressional role in health and safety
issues).
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